<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827943</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-08</org_study_id>
    <nct_id>NCT01827943</nct_id>
  </id_info>
  <brief_title>Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer</brief_title>
  <acronym>VESTOR</acronym>
  <official_title>Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the absence of standard treatment in this indication, this test evaluates a new drug type&#xD;
      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the absence of standard treatment in this indication, this test evaluates a new drug type&#xD;
      targeted therapy in this indication, evaluating its efficacy in terms of tumor response and&#xD;
      survival. This study will also search for genes involved in the response to treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-progression Rate at 2 Months</measure>
    <time_frame>2 months</time_frame>
    <description>Non-progression rate is defined as the rate of participants in complete or partial response or stable disease according to RECIST V1.1.&#xD;
Complete response is defined as the disappearance of all target lesions, partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and stable disease occurs when neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progression, taking as reference the smallest sum diameters while on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through Database Cutoff Date of 23-Jan-2015 (up to approximately 5 years and 7 months - median follow-up time of 14 months)</time_frame>
    <description>OS was was defined as the time from the treatment initiation to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Through Database Cutoff Date of 23-Jan-2015 (up to approximately 5 years and 7 months - median follow-up time of 14 months)</time_frame>
    <description>Progression-free survival (PFS) was defined as the time from the initiation of treatment to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Patients alive and progression free were censored at the date of last follow-up or last patient contact. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Relapsed Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women of at least 18 years of age&#xD;
&#xD;
          -  Histologically proven Bladder cancer&#xD;
&#xD;
          -  Locally advanced or metastatic disease (stage IV)&#xD;
&#xD;
          -  Functional status (ECOG / OMS) ≤ 2&#xD;
&#xD;
          -  Relapse after first-line chemotherapy&#xD;
&#xD;
          -  Measurable lesions (RECIST criteria)&#xD;
&#xD;
          -  Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.&#xD;
&#xD;
          -  Biological levels :&#xD;
&#xD;
          -  Neutrophil count &gt;1,5.109/L.&#xD;
&#xD;
          -  Platelets &gt;100.109/L&#xD;
&#xD;
          -  Total serum bilirubin &lt; 1.5 × ULN&#xD;
&#xD;
          -  Clearance of créatinine 40 ml/mm&#xD;
&#xD;
          -  If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase&#xD;
             (AST) &lt;2.5 × ULN&#xD;
&#xD;
          -  With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;5 ×&#xD;
             ULN&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Both women and men must agree to use a medically acceptable method of contraception&#xD;
             throughout the study. Women of childbearing potential must have a negative serum&#xD;
             pregnancy test of or less than 7 days before the first perfusion of study.&#xD;
&#xD;
          -  France only : Patients affiliated to a social security program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of metastatic brain or meningeal tumors on selection scanner, weither&#xD;
             symptomatic or asymptomatic&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion&#xD;
&#xD;
          -  Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or&#xD;
             polysorbate 80 or to their excipients&#xD;
&#xD;
          -  Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma&#xD;
             curatively treated) or incidental (≤ pT2) prostate cancer found on a radical&#xD;
             cystoprostatectomy material&#xD;
&#xD;
          -  The drugs known as CYP3A4/5 inhibitors or inducers will specifically be excluded on&#xD;
             the 30th day ( or at least 7 halves-lives, according to the shortest duration) before&#xD;
             the first perfusion and throughout the study. Any food known to inhibit CYP3A4/5 (for&#xD;
             example grapefruit, grapefruit juice, star-fruit or star-fruit juice) will also be&#xD;
             purposely excluded.&#xD;
&#xD;
          -  Auto-immune pathology, psychiatric or neurological disorder&#xD;
&#xD;
          -  Any unstable medical condition&#xD;
&#xD;
          -  Unstable cardiac disease&#xD;
&#xD;
          -  Severe renal failure&#xD;
&#xD;
          -  Unstable diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient enrolled in another therapeutic clinical trial&#xD;
&#xD;
          -  Patient unable to follow and comply with the study procedures because of any&#xD;
             geographical, social or medical condition&#xD;
&#xD;
          -  Patient partially or totally deprived of his civil rights&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine HOUEDE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'instruction des armées du Val-de-Grâce</name>
      <address>
        <city>Paris</city>
        <zip>75230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Pulido M, Roubaud G, Cazeau AL, Mahammedi H, Vedrine L, Joly F, Mourey L, Pfister C, Goberna A, Lortal B, Bellera C, Pourquier P, Houédé N. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer. 2018 Feb 17;18(1):194. doi: 10.1186/s12885-018-4059-5.</citation>
    <PMID>29454321</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <results_first_submitted>March 15, 2021</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2021</results_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Temsirolimus</title>
          <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.&#xD;
Temsirolimus: Temsirolimus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never treated because of an rapid progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temsirolimus</title>
          <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.&#xD;
Temsirolimus: Temsirolimus</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" lower_limit="41.0" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Non-progression Rate at 2 Months</title>
        <description>Non-progression rate is defined as the rate of participants in complete or partial response or stable disease according to RECIST V1.1.&#xD;
Complete response is defined as the disappearance of all target lesions, partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and stable disease occurs when neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progression, taking as reference the smallest sum diameters while on study.</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temsirolimus</title>
            <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.&#xD;
Temsirolimus: Temsirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Non-progression Rate at 2 Months</title>
          <description>Non-progression rate is defined as the rate of participants in complete or partial response or stable disease according to RECIST V1.1.&#xD;
Complete response is defined as the disappearance of all target lesions, partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and stable disease occurs when neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progression, taking as reference the smallest sum diameters while on study.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="33.7" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>OS was was defined as the time from the treatment initiation to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.</description>
        <time_frame>Through Database Cutoff Date of 23-Jan-2015 (up to approximately 5 years and 7 months - median follow-up time of 14 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temsirolimus</title>
            <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.&#xD;
Temsirolimus: Temsirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>OS was was defined as the time from the treatment initiation to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="5.2" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival (PFS) was defined as the time from the initiation of treatment to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Patients alive and progression free were censored at the date of last follow-up or last patient contact. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data.</description>
        <time_frame>Through Database Cutoff Date of 23-Jan-2015 (up to approximately 5 years and 7 months - median follow-up time of 14 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Temsirolimus</title>
            <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.&#xD;
Temsirolimus: Temsirolimus</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival (PFS) was defined as the time from the initiation of treatment to the first documented progression (as per RECIST v1.1) or death (due to any cause), whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Patients alive and progression free were censored at the date of last follow-up or last patient contact. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.8" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Temsirolimus</title>
          <description>Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.&#xD;
Temsirolimus: Temsirolimus</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Blood/Bone Marrow (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Obstruction, GI</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>GASTROINTESTINAL (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify, __)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <description>PAIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <description>HEPATOBILIARY / PANCREAS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <description>INFECTION (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <description>INFECTION (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>MUSCULOSKELETAL/SOFT TISSUE (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelets</sub_title>
                <description>Blood/Bone Marrow (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <description>METABOLIC LABORATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, __)</sub_title>
                <description>MUSCULOSKELETAL/SOFT TISSUE (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>PAIN (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <description>HEMORRHAGE/BLEEDING (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <description>NEUROLOGY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <description>NEUROLOGY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify, __)</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <description>PULMONARY / UPPER RESPIRATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, __)</sub_title>
                <description>PULMONARY / UPPER RESPIRATORY (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Blood/Bone Marrow (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="40" subjects_affected="26" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, __)</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Obstruction, GI</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify, __)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Edema:limb</sub_title>
                <description>LYMPHATICS (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>PAIN (SOC from CTCAEV3.0)</description>
                <counts group_id="E1" events="61" subjects_affected="29" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, __)</sub_title>
                <description>PAIN (SOC from CTCAEV3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, __)</sub_title>
                <description>INFECTION (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="45" subjects_affected="31" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <description>Blood/Bone Marrow (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <description>Blood/Bone Marrow (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, __)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <description>METABOLIC/LABORATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, __)</sub_title>
                <description>MUSCULOSKELETAL/SOFT TISSUE (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <description>Gastrointestinal (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>NEUROLOGY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <description>NEUROLOGY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>CONSTITUTIONAL SYMPTOMS (SOC from CTCAE v3.0)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <description>NEUROLOGY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU</sub_title>
                <description>HEMORRHAGE/BLEEDING (SC from CTCAE V3.0)</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify, __)</sub_title>
                <description>RENAL/GENITOURINARY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory</sub_title>
                <description>HEMORRHAGE/BLEEDING (SC from CTCAE V3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>PULMONARY/UPPER RESPIRATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <description>PULMONARY/UPPER RESPIRATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, __)</sub_title>
                <description>PULMONARY/UPPER RESPIRATORY (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, __)</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <description>DERMATOLOGY/SKIN (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>CARDIAC GENERAL (SOC from CTCAE V3.0)</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Nadine Houede, oncologist</name_or_title>
      <organization>Institut Bergonie</organization>
      <phone>05.56.33.33.33</phone>
      <email>nadine.HOUEDE@chu-nimes.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

